Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - dasatinib - filmtablette - teil 1 - filmtablette; dasatinib (34199) 50 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - dasatinib 1 h<2>o - filmtablette - teil 1 - filmtablette; dasatinib 1 h<2>o (34200) 82,954 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - dasatinib 1 h<2>o - filmtablette - teil 1 - filmtablette; dasatinib 1 h<2>o (34200) 103,693 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - dasatinib 1 h<2>o - filmtablette - teil 1 - filmtablette; dasatinib 1 h<2>o (34200) 72,585 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ratiopharm gmbh (3087881) - dasatinib 1 h<2>o - filmtablette - teil 1 - filmtablette; dasatinib 1 h<2>o (34200) 51,847 milligramm

Euroopan unioni - saksa - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Euroopan unioni - saksa - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.